Publications by authors named "Yu-Mei Ren"
Front Pharmacol
August 2021
Article Synopsis
- Anti-PD-1 therapy is effective for treating carcinomas but can lead to serious skin adverse effects, including severe bullous skin reactions (SBSR) and toxic epidermal necrolysis (TEN).
- A case study is presented where a cervical cancer patient developed SBSR after receiving multiple cycles of Sintilimab and Toripalimab, resulting in severe rashes and complications that ultimately led to death.
- The study highlights the importance for healthcare providers to monitor patients closely for early signs of skin toxicity from anti-PD-1 therapy and to provide timely treatments to prevent severe outcomes.
